Louisiana bars boards from blocking peptide compounding that meets federal law. BPC-157 does not yet meet it.

Louisiana's legislature voted without a single dissent this spring to stop the state's licensing boards, medical and pharmacy boards among them, from blocking peptide prescribing and compounding. The protection in Act 374 reaches only compounding that is in compliance with 21 U.S.C. 353a, the federal compounding statute, and under that statute BPC-157 and the five other peptides in last week's federal compounding notice cannot yet lawfully be compounded at all.

The Louisiana law was signed on May 22 and took effect on August 1. On October 30 the U.S. Department of Health and Human Services published a notice saying it will not take enforcement action against licensed pharmacies and physicians that compound BPC-157, TB-500, KPV, MOTS-c, epitalon or semax. The notice is explicit that this is a pause, not a permission: it applies while the list of bulk drug substances that can be used in compounding under section 503A of the FD&C Act (the 503A bulks list) is developed through rulemaking.

Read quickly, the two documents look like a matching pair: a state that forbids its boards to block peptide compounding, and a federal department that says it will not block it either. On their words they do not fit. Louisiana protects compounding that complies with federal law; HHS has promised not to enforce federal law against compounding that does not. The legislature had a version of the bill that would have fit the federal policy exactly. It replaced that version in March, three weeks before FDA took the step the dropped language was waiting for.

What Louisiana's peptide law says

Act 374 of 2026, Senate Bill 253 by Senator Patrick McMath, adds a section to Title 37 of the Louisiana Revised Statutes under the heading Peptides; prohibited regulations. It is two sentences long, and each is addressed to the licensing boards rather than to the licensees.

A. No professional or occupational licensing board shall prohibit a healthcare provider with prescriptive authority from providing patients with peptides shipped from either of the following: (1) A FDA-registered 503B outsourcing facility that is in compliance with 21 U.S.C. 353b. (2) A 503A compounding pharmacy that is in compliance with 21 U.S.C. 353a and applicable United States Pharmacopeia - National Formulary chapters.

B. No professional or occupational licensing board shall prohibit a Louisiana licensed pharmacist in a state permitted pharmacy from compounding and dispensing peptides as long as the Louisiana licensed pharmacist in the state permitted pharmacy is in compliance with 21 U.S.C. 353a and applicable United States Pharmacopeia - National Formulary chapters.

The bill passed the Senate 35 to 0 on March 23 and the House 98 to 0 on May 7, and the Senate accepted the House's amendments 37 to 0 on May 18. Across three roll calls, no Louisiana legislator voted against it. The law names no peptide and defines none. Its only test is the federal one.

Section 503A decides which peptides the law protects

Section 503A of the Federal Food, Drug, and Cosmetic Act is what lets a licensed pharmacist compound a drug for an individual prescription without that drug going through FDA approval. It sets conditions, and the first concerns the raw ingredient. A bulk drug substance qualifies only if it meets one of three tests. It has a United States Pharmacopeia or National Formulary monograph; or, with no monograph, it is among the components of drugs approved by the Secretary; or, failing both, it appears on a list developed by the Secretary through regulations.

That list is the 503A bulks list. The six peptides in the HHS notice are on the path to it precisely because they meet neither of the first two tests: no monograph, and no approved drug contains them. FDA's Pharmacy Compounding Advisory Committee voted in July to recommend them for the list. A recommendation is not a regulation, and the HHS notice says in its own words that adding them is something FDA's future rulemakings may propose. Until a final rule puts a peptide on the list, a pharmacy compounding it from bulk powder is not compounding in compliance with section 503A.

Not enforcing a law is not the same as complying with it, and Louisiana's peptide statute asks for compliance.

The HHS notice does not claim otherwise. It is a statement that the department does not intend to take enforcement action, and it says it does not establish any rights for any person and is not binding on HHS or the public. The department says it may revisit the policy if, among other things, a safety signal or product quality issue arises. A Louisiana pharmacist compounding BPC-157 under the HHS policy is doing something the federal government has chosen to tolerate, not something section 503A allows.

The outsourcing-facility route in the first sentence of the Louisiana law does not help either. Section 503B, the statute for larger outsourcing facilities, has its own bulk-substance test: a list of substances for which FDA finds a clinical need, or a drug on the national shortage list. None of the six peptides is on either, and the HHS policy is limited by its title to compounding under section 503A.

The Category 2 peptide trigger the Louisiana Senate dropped

The bill as first filed in February was shorter and looser. It would have protected prescribers using peptides from a 503A compounding pharmacy that buys its active pharmaceutical ingredients from an FDA-registered manufacturer, and required the prescriber to check that the peptide was not on FDA's prohibited compounding list. It said nothing about section 503A compliance.

The Senate Health and Welfare Committee rewrote it on March 11 around a different federal marker: FDA's Category 2, the agency's interim list of bulk substances that raise significant safety risks, where BPC-157 and the other five peptides then sat. The committee's text would have barred the boards from stopping a pharmacy compounding any peptide not on the prohibited list or in Category 2, and added:

Once a peptide is removed from the FDA Category 2 list, a state-licensed compounding pharmacy may compound such peptide provided the active pharmaceutical ingredient is obtained from an FDA-registered manufacturer and the pharmacy otherwise complies with all applicable federal and state compounding laws and regulations.

On March 23 Senator McMath moved floor amendments that deleted the Category 2 language and replaced it with the section 503A compliance test now in the law. The Senate adopted them and passed the bill the same day. On April 15, FDA announced it was removing BPC-157, TB-500, KPV, MOTS-c, semax, epitalon and six other peptides from Category 2. Under the committee's version, that announcement would have opened the door in Louisiana for every one of them. Under the version that became law, it changed nothing, because leaving Category 2 does not put a peptide on the 503A bulks list.

The House made one more cut. Its Health and Welfare Committee, voting 10 to 0 on April 28, removed the clause requiring prescribers to make sure the peptides they prescribe were prepared under the federal conditions. The obligation to comply with section 503A now sits only with the pharmacy, and the protection depends on it.

The written bill record does not say why the Category 2 trigger was dropped. The floor amendment is a single page of replacement text.

Louisiana and the three states that barred research-grade peptides

Louisiana went the other way from Alabama, Mississippi and South Carolina. Between May and August, their boards told licensees that under no circumstances is it permissible to compound or dispense a research-grade peptide. Those notices are set out here. The direction is opposite. On the six HHS peptides, the practical distance is smaller than it looks.

The three boards drew their line at material that is not FDA-approved or that is sold as research-grade, and required every ingredient to come from a source the state pharmacy board permits. Louisiana drew its line at federal compliance. Act 374 forbids a board to prohibit compounding that complies with section 503A. It says nothing about compounding that does not. On the text, a Louisiana board keeps whatever authority it had over peptide compounding outside section 503A, including compounding of the six peptides under the HHS policy, until FDA lists them.

Ohio's Board of Pharmacy reached the same place as the three no-circumstances states through suspension orders rather than a notice, according to a law firm's review of its published orders. No Louisiana board has yet said how it reads the new section. We found no guidance on Act 374 from the Louisiana Board of Pharmacy, the Louisiana State Board of Medical Examiners or the Louisiana State Board of Nursing on their websites or in public reporting as of November 2.

The case for the broader reading of the peptide law

The opposite reading has real support. The section's heading is Peptides; prohibited regulations, and its evident purpose is to keep the state's boards from forbidding peptide prescribing and compounding. A law passed 35 to 0 and 98 to 0 to protect peptide compounding would be close to empty if it protected none of the peptides anyone is compounding.

The argument from federal practice is stronger. Compliance with section 503A is, in the real world, measured by the federal regulator that enforces it. HHS has now said in a signed notice that it will not act against compounding the six peptides. Its conditions, as counsel who have read the policy summarize them, track section 503A closely: a registered manufacturer named on the certificate of analysis, a valid certificate covering identity and impurities, a prescription for a named individual. A pharmacy meeting every one of those conditions meets the sourcing requirements of section 503A; what it lacks is the list. A Louisiana board that disciplined it would be enforcing a federal requirement the federal government has set aside, and that pharmacy would have a plausible claim under the new section.

That is a serious argument. It is also the argument the Senate's committee text would have made unnecessary. A legislature that writes in compliance with 21 U.S.C. 353a in place of a trigger built for exactly this situation has chosen the statute's words, and a court reads the words first. Until a Louisiana board or court says which reading governs, a pharmacist relying on Act 374 to compound BPC-157 is relying on an interpretation, not on the text.

What Louisiana's law means for research-grade peptides

Nothing new. Act 374 protects two channels, 503A pharmacies and 503B outsourcing facilities, and only when they comply with federal law. Section 503A requires that a bulk substance be made by an establishment registered with FDA and arrive with valid certificates of analysis for each bulk drug substance. Peptide sold as a research chemical, labeled for laboratory use, without a registered drug establishment behind it or a certificate meeting the federal standard, cannot become a compounding ingredient in Louisiana under this law any more than it could before. The original bill made the same point in plain words, requiring active ingredients from an FDA-registered manufacturer. The enacted text reaches it through the federal statute. For research-grade peptides, the line in Louisiana is where it is in the three no-circumstances states: in the laboratory.

What to watch on Louisiana's peptide law

• The HHS docket. Comments on the peptide policy close November 13 on docket HHS-OASH-2026-0496. As of this morning the docket shows two documents and no comments.
• The FDA rule. The day a final rule adds BPC-157 or any of the other five to the 503A bulks list is the day Louisiana's law begins to protect compounding it, without another vote in Baton Rouge.
• The Louisiana boards. Whether the Board of Pharmacy or the Board of Medical Examiners issues guidance on R.S. 37:23.5, and whether it reads the HHS policy as compliance.
• Copies. Whether other legislatures adopt Louisiana's text in 2027, and whether they keep the section 503A test or write a trigger tied to the HHS policy.

Frequently asked questions

What does Louisiana's peptide law, Act 374, do?

It bars Louisiana's professional and occupational licensing boards from prohibiting prescribers from providing peptides shipped from a compliant 503A pharmacy or 503B outsourcing facility, and from prohibiting pharmacists from compounding peptides in compliance with 21 U.S.C. 353a. It was signed May 22, 2026, took effect August 1, 2026, and is codified at La. R.S. 37:23.5.

Is BPC-157 compounding legal in Louisiana?

Not clearly. Act 374 protects only compounding that complies with section 503A, which requires a bulk substance to have a monograph, be part of an approved drug, or appear on the 503A bulks list. BPC-157 meets none of these yet. HHS has said it will not take enforcement action, but that is not compliance, and no Louisiana board has said how it reads the law. This is not legal advice.

Does the HHS peptide policy count as compliance with section 503A?

On its own terms, no. The notice says HHS does not intend to take enforcement action while the 503A bulks list is developed through rulemaking, and that the policy is not binding on HHS or the public. A substance becomes compliant when a final rule places it on the list.

What changed in Louisiana's peptide bill before it passed?

The Senate committee's version would have allowed compounding of any peptide removed from FDA's Category 2 list. On March 23 the Senate replaced that with a requirement of compliance with section 503A. FDA removed BPC-157 and 11 other peptides from Category 2 on April 15, which would have triggered the dropped language but does not satisfy the enacted one.

Does Act 374 let research-grade peptides be used in Louisiana compounding?

No. Section 503A requires bulk substances from an FDA-registered establishment with valid certificates of analysis. Material sold as a research chemical does not meet that standard, and the Louisiana law adds no other route.

Sources & Further Reading

1. Louisiana Legislature. Senate Bill 253, 2026 Regular Session, by Senator McMath. Original (prefiled February 26, 2026), Engrossed, Reengrossed and Enrolled texts.
2. Louisiana Legislature, SB 253 amendments: Senate Committee Amendments No. 780 (Health and Welfare, adopted March 16, 2026); Senate Floor Amendments No. 1121 (McMath, adopted March 23, 2026); House Committee Amendments No. 4684 (Health and Welfare, April 28, 2026); Senate Summary of House Amendments. Résumé Digest for Act 374 and bill history, legis.la.gov, read November 2, 2026.
3. Louisiana Legislature. Roll calls on SB 253: Senate final passage, 35–0, March 23, 2026; House final passage, 98–0, May 7, 2026; Senate concurrence, 37–0, May 18, 2026.
4. Act 374 of the 2026 Regular Session, enacting La. R.S. 37:23.5, signed by the Governor May 22, 2026, effective August 1, 2026.
5. Federal Food, Drug, and Cosmetic Act § 503A, 21 U.S.C. § 353a(b)(1)(A); § 503B, 21 U.S.C. § 353b(a)(2)(A).
6. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. 91 FR 68526–68527, October 30, 2026, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496, RIN 0910-ZD94. The policy document itself could not be retrieved for this piece; its conditions are as summarized by counsel and set out in this library's piece of October 30.
7. Food and Drug Administration. Removal of peptides from Category 2 of the interim bulk drug substances policy. 91 FR 20465, April 16, 2026, FR Doc. 2026-07361, Docket FDA-2025-N-6895.
8. regulations.gov, Docket HHS-OASH-2026-0496: two documents, no comments, as listed on the morning of November 2, 2026.
9. Alabama Board of Medical Examiners, May 26, 2026; South Carolina Board of Medical Examiners, August 18, 2026; Mississippi Boards of Medical Licensure, Nursing and Pharmacy, August 19, 2026. Notices on research-grade peptides, as cited in this library's piece of November 1.
10. Frier Levitt. Peptides Under the Microscope: Recent FDA and State Enforcement Trends, 2026; review of the Ohio Board of Pharmacy's published orders involving peptide products.

Cosmic Peptides. (2026, November 2). Louisiana bars boards from blocking peptide compounding that meets federal law. BPC-157 does not yet meet it.. Cosmic Peptides Research Library. Retrieved November 2, 2026, from https://cosmicpeptides.com/research/perspectives/louisiana-peptide-law

@misc{cosmicpeptides_research_perspectives_louisiana_peptide_law,
  author       = {{Cosmic Peptides}},
  title        = {Louisiana bars boards from blocking peptide compounding that meets federal law. BPC-157 does not yet meet it.},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = nov,
  url          = {https://cosmicpeptides.com/research/perspectives/louisiana-peptide-law},
  urldate      = {2026-11-02},
  note         = {Last reviewed 2026-11-02}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - Louisiana bars boards from blocking peptide compounding that meets federal law. BPC-157 does not yet meet it.
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/11/02
UR  - https://cosmicpeptides.com/research/perspectives/louisiana-peptide-law
Y2  - 2026/11/02
LA  - en
ER  -